News articles about ImmuCell Corporation (NASDAQ:ICCC) have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. ImmuCell Corporation earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.0327715961469 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news headlines that may have impacted Accern Sentiment’s analysis:
- ImmuCell Corporation (ICCC) Releases Earnings Results (americanbankingnews.com)
- Edited Transcript of ICCC earnings conference call or presentation 13-Nov-17 9:30pm GMT (finance.yahoo.com)
- ImmuCell Corp’s (ICCC) CEO Michael Brigham on Q3 2017 Results – Earnings Call Transcript (seekingalpha.com)
- Immucell Corp (ICCC) Announces USDA Approval of New Product Claim to Prevent Rotavirus Infections (streetinsider.com)
- ImmuCell Achieves USDA Approval of New Product Claim to Prevent Rotavirus Infections (finance.yahoo.com)
ImmuCell Corporation (NASDAQ ICCC) traded up $0.24 on Tuesday, reaching $8.40. The company had a trading volume of 28,700 shares, compared to its average volume of 7,823. The company has a market cap of $41.19, a P/E ratio of 90.67 and a beta of 1.16. ImmuCell Corporation has a twelve month low of $4.76 and a twelve month high of $8.83. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.89 and a quick ratio of 1.28.
ImmuCell Corporation (NASDAQ:ICCC) last released its quarterly earnings results on Monday, November 13th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter. The firm had revenue of $2.01 million during the quarter. ImmuCell Corporation had a net margin of 4.55% and a return on equity of 2.25%.
Separately, ValuEngine upgraded ImmuCell Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, October 18th.
ILLEGAL ACTIVITY WARNING: This story was published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://sportsperspectives.com/2017/11/14/immucell-corporation-iccc-receives-media-impact-score-of-0-13.html.
About ImmuCell Corporation
ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis.
Receive News & Ratings for ImmuCell Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell Corporation and related companies with MarketBeat.com's FREE daily email newsletter.